Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Drug Deliv ; 29(1): 342-350, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-35049388

RESUMEN

PURPOSE: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and this study aimed to develop a conatumumab decorated, irinotecan prodrug and quercetin co-loaded delivery system for combined and targeted colorectal cancer treatment. METHODS: A conatumumab (C) decorated, irinotecan prodrug (I-p) and quercetin (Q) co-encapsulated NLC (C I-p/Q NLC) was developed. In vitro and in vivo antitumor efficiency of NLC was evaluated on CRC cells and mice xenograft. RESULTS: The results showed that the HT-29 cells uptake of C I-p/Q NLC was over 70%. Reactive oxygen species (ROS) sensitive irinotecan prodrug formulation showed improved drug release ability in hypoxic conditions. C I-p/Q NLC showed significantly higher cytotoxicity than non-decorated NLC, single drug-loaded NLC and free drugs. In vivo studies in a CRC-bearing model corroborated the capability of nanoparticles for the inhibition of cancer, leading to a reduction of tumor growth without systemic toxicity. CONCLUSION: The conatumumab decorated, ROS sensitive prodrug contained combination nano-system is a promising platform for CRC therapy.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Antineoplásicos/farmacología , Irinotecán/farmacología , Sistema de Administración de Fármacos con Nanopartículas/química , Quercetina/farmacología , Animales , Anticuerpos Monoclonales/administración & dosificación , Antineoplásicos/administración & dosificación , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Portadores de Fármacos/química , Combinación de Medicamentos , Liberación de Fármacos , Estabilidad de Medicamentos , Sinergismo Farmacológico , Células HT29 , Humanos , Irinotecán/administración & dosificación , Lípidos/química , Ratones , Nanoestructuras , Tamaño de la Partícula , Profármacos , Quercetina/administración & dosificación , Especies Reactivas de Oxígeno , Propiedades de Superficie , Ensayos Antitumor por Modelo de Xenoinjerto
2.
J Cancer Res Ther ; 11(3): 658, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26458663

RESUMEN

Mucoepidermoid carcinoma (MEC) is typically located in the salivary, lacrimal, and tracheobronchial glands and rarely presents in the esophagus. MEC is commonly characterized by squamous cells, mucus-secreting cells, and intermediate cells. This report presents the case of a 57-years-old male with a three months history of cough and shortness of breath. Computer tomography (CT) scans revealed a tumor locating in the left hilar. The histological report was squamous carcinoma. After three circles of chemotherapy, the patient complained of dysphagia. The electronic gastroscope showed a protrusion which 30-34 cm from the incisors. The tumor was histopathologically determined to be MEC of esophagus. The patient refused to surgery and concurrent chemoradiotheray; so, radiotherapy and sequential chemotherapy were performed, and after one year of follow up, the disease of esophagus recurrence; the patient was died of hemorrhage of esophagus for tumor progression. The literatures of MEC are also reviewed in this study.


Asunto(s)
Carcinoma Mucoepidermoide/diagnóstico por imagen , Carcinoma de Células Escamosas/diagnóstico por imagen , Neoplasias Esofágicas/diagnóstico por imagen , Neoplasias Pulmonares/diagnóstico por imagen , Carcinoma Mucoepidermoide/patología , Carcinoma Mucoepidermoide/terapia , Carcinoma de Células Escamosas/terapia , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/terapia , Resultado Fatal , Humanos , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico por imagen , Recurrencia Local de Neoplasia/prevención & control , Cintigrafía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA